French pharmaceutical giant Sanofi is making a significant investment in India, with plans to invest €400 million ($437 million) in its global capacity center (GCC) in Hyderabad by 2030. The company’s commitment to India extends beyond financial investment, as it aims to more than double its workforce in Hyderabad over the next two years, from 1,000 employees to 2,600 by 2026. This expansion will focus on hiring data scientists and engineers, strengthening its digital team and leveraging AI tools to drive innovation and efficiency.
Sanofi’s Hyderabad GCC is strategically important, serving as its largest globally and playing a crucial role in supporting operations in the US and France. The facility will handle a significant amount of documentation for drug clinical trials, contributing to Sanofi’s global drug development efforts.
Advertisement
Hey there! Want to support us? If you’re planning on shopping on Amazon, please consider using amzn.to/4bPDFNL. It doesn’t cost you anything extra, but helps us keep the lights on. Thanks for your support!
The decision to invest heavily in India is driven by several key factors. India offers a readily available pool of skilled talent at competitive costs, making it an attractive location for companies seeking to expand their workforce. The country’s business-friendly policies and growing economy also contribute to its appeal as a destination for foreign investment. Furthermore, as companies seek to diversify their supply chains away from China, India presents an attractive alternative.
EY estimates that India’s domestic GCC market will more than double to $110 billion by 2030, driven by factors like a skilled workforce and a conducive business environment. This growth is fueled by the increasing demand for outsourcing services from companies across various sectors. Sanofi’s investment in its Hyderabad GCC reflects its commitment to India as a strategic hub for its global operations.